Ayumi Fujimoto

Osaka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Treatment landscape of mature NK/T-cell lymphomas: treatment outcomes in Japan and future prospects

Treatment landscape of mature NK/T-cell lymphomas: treatment outcomes in Japan and future prospects

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: August 30, 2026

TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial.

TFH phenotype and response to tucidinostat in relapsed/refractory PTCL: analysis of patients from a phase IIb trial.

Journal: International journal of hematology

Published: March 18, 2026

Association of Probiotics with Effectiveness of Nivolumab or Pembrolizumab in Patients with Esophageal Cancer Taking Proton Pump Inhibitors: A Multicenter Retrospective Study.

Association of Probiotics with Effectiveness of Nivolumab or Pembrolizumab in Patients with Esophageal Cancer Taking Proton Pump Inhibitors: A Multicenter Retrospective Study.

Journal: Journal of gastrointestinal cancer

Published: February 06, 2026

Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: the phase II NCCH1903/ATTACK trial.

Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: the phase II NCCH1903/ATTACK trial.

Journal: Blood advances

Published: February 04, 2026

Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: phase 2 of NCCH1903/ATTACK trial.

Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: phase 2 of NCCH1903/ATTACK trial.

Journal: Blood advances

Published: February 04, 2026

Association of probiotic use with nivolumab efficacy in gastric cancer patients on gastric acid suppressants.

Association of probiotic use with nivolumab efficacy in gastric cancer patients on gastric acid suppressants.

Journal: iScience

Published: January 21, 2026

Mechanism of vildagliptin-induced liver injury: An idiosyncratic drug reaction mediated by inflammasome activation.

Mechanism of vildagliptin-induced liver injury: An idiosyncratic drug reaction mediated by inflammasome activation.

Journal: International immunopharmacology

Published: November 01, 2025

Advanced Classical Hodgkin Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.

Advanced Classical Hodgkin Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.

Journal: JCO global oncology

Published: October 29, 2025

Peripheral T-Cell Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.

Peripheral T-Cell Lymphoma Management in East and Southeast Asia: Real-World Challenges and Aspirations of the Asian Lymphoma Study Group.

Journal: JCO global oncology

Published: October 22, 2025

Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.

Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.

Journal: Leukemia

Published: August 22, 2025

Impact of Achieving Progression-Free Survival 24 on Subsequent Overall Survival in Diffuse Large B-Cell Lymphoma Patients.

Impact of Achieving Progression-Free Survival 24 on Subsequent Overall Survival in Diffuse Large B-Cell Lymphoma Patients.

Journal: Cancer science

Published: July 16, 2025

High-accuracy Detection of PD-L1 3'-UTR Disruption by Immunohistochemistry and Fluorescence in Situ Hybridization on Formalin-fixed Paraffin-embedded Sections.

High-accuracy Detection of PD-L1 3'-UTR Disruption by Immunohistochemistry and Fluorescence in Situ Hybridization on Formalin-fixed Paraffin-embedded Sections.

Journal: The American journal of surgical pathology

Published: March 03, 2025

Showing 1-12 of 56

Last Updated: 09/26/2026